English
Regional settings| Spread | 0.09 | ||||
 Long position overnight feeLong position overnight fee
Trade size with leverage ~ US$5,000.00 Short position overnight fee ~ US$4,000.00 | -0.026179% | ||||
| Short position overnight fee Short position overnight fee
Trade size with leverage ~ US$5,000.00 Short position overnight fee ~ US$4,000.00 | 0.003957% | ||||
| Overnight fee time | 21:00 (UTC) | ||||
| Currency | USD | ||||
| Min traded quantity | 1 | ||||
| Margin | 20 | ||||
| Stock exchange | United States of America | ||||
| Commission on trade1 | 0% |
Information_provided_by_capital
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information
| Prev. Close | 7.37 |
| Open | 7.3 |
| 1-Year Change | -1.88% |
| Day's Range | 7.3 - 7.66 |
Voyager Therapeutics, Inc. is a clinical-stage gene therapy company that is focused on developing treatments for patients suffering from severe neurological diseases. The Company's pipeline consists of programs for severe neurological indications, including Huntington’s disease; a monogenic form of amyotrophic lateral sclerosis (ALS); and tau-related diseases including Alzheimer’s disease, frontotemporal dementia (FTD) and progressive supranuclear palsy (PSP). Its pipeline is also focused on advancing gene therapies that leverage AAV capsids (TRACER) and vectorized antibodies. It is focused on identifying AAV capsids, which are the outer viral protein shells that enclose the genetic material of the virus payload. The Company is developing vectorized antibodies, including vectorized antibody compounds, which consist of a virus vector genome that encodes approximately one or more antibodies that target and bind to a tau protein.
BRIEF: For the fiscal year ended 31 December 2021, Voyager Therapeutics Inc revenues decreased 78% to $37.4M. Net loss totaled $71.2M vs. income of $36.7M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Net loss reflects Research and Development increase of 21% to $69.7M (expense), Other income decrease of 63% to $2.8M (income).
